Skip to main content
Androgen therapy in women
  • Julie M. Wickman, Philadelphia College of Osteopathic Medicine
  • Ashley Groves
  • Lauren Wiggins
  • Nishman Patel
Document Type
Publication Date
Approximately 43% of women in the United States between the ages of 18 and 59 years experience sexual dysfunction. Hypoactive sexual desire disorder (HSDD) is characterized by the absence of sexual fantasies and desire for sexual activity. Male sexual dysfunction has been extensively researched, but there is less evidence addressing the treatment of HSDD in women, particularly with regard to the use of androgen therapy. There are no FDA-approved testosterone treatments for women, despite the fact that 4 million prescriptions have been written off-label for HSDD. This highlights the need for more research on safety, efficacy, side effects, and transference issues.

This article was published in U.S.Pharmacist, Volume 39, Issue 8, Pages 42-46.

The published version is available at .

Copyright © 2014 U.S. Pharmacist.

Citation Information
Julie M. Wickman, Ashley Groves, Lauren Wiggins and Nishman Patel. "Androgen therapy in women" U.S.Pharmacist Vol. 39 Iss. 8 (2014) p. 42 - 46
Available at: